Afshan Zahedi

Dr. Afshan Zahedi

Thyroid Program, Women’s College Hospital, 76 Grenville Street, Toronto, ON M5S 1B2, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2024 in Thyroid®
Verified
Journal Article
Open access
ASAnna Sawka
Anna Sawka
SGSangeet Ghai
Sangeet Ghai
LRLorne Rotstein
Lorne Rotstein
JIJonathan C. Irish
Jonathan C. Irish
JPJesse D. Pasternak
Jesse D. Pasternak
DGDavid Goldstein
David Goldstein
Background: It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. Methods: We performed a prospective observational cohort study of Canadian patients with small (<2 cm) low-risk papillary thyroid cancer (PTC) who were offered the choice of active surveillance (AS) or surgery ( Clinicaltrials.gov NCT03271892). Participants completed a questionnaire one year after their treatment decision. The primary intention-to-treat analysis compared the mean decision regret scale total score between patients who chose AS or surgery. A secondary analysis examined one-year decision regret score according to treatment status. Secondary outcomes included quality of life, mood, fear of disease progression, and body image perception. We adjusted for age, sex, and follow-up duration in linear regression analyses. Results: The overall questionnaire response rate was 95.5% (191/200). The initial treatment choices of respondents were AS 79.1% (151/191) and surgery 20.9% (40/191). The mean age was 53 years (standard deviation [SD] 15 years) and 77% (147/191) were females. In the AS group, 7.3% (11/151) of patients crossed over to definitive treatment (two for disease progression) before the time of questionnaire completion. The mean level of decision regret did not differ significantly between patients who chose AS (mean 22.4, SD 13.9) or surgery (mean 20.9, SD 12.2) in crude ( p = 0.730) or adjusted ( p = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3–18.9], p = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS ( p = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. Conclusions: In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.

14 October 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
PNPatricia Nguyen
Patricia Nguyen
PAParsa Azizi-Mehr
Parsa Azizi-Mehr
CTCarol Townsley
Carol Townsley
AZAfshan Zahedi
Afshan Zahedi
Background: Recently published clinical pathways for management of thyroid cancer outlined the criteria for transitioning low-risk patients to primary care within one to five years from diagnosis. However, discharge patterns among endocrinologists remain heterogeneous as there lacks a consensus regarding post-treatment care for thyroid cancer patients. Objective: This study described general characteristics and outcomes of thyroid cancer patients who were discharged from specialist care and transitioned to a primary care-based follow-up clinic. Methods: Thyroid cancer patients seen in the After Cancer Treatment Transition (ACTT) clinic at Women’s College Hospital (Toronto, Canada) were included in the study. Electronic medical records were reviewed between May and October 2021 to collect patient characteristics and outcomes. Descriptive statistics were calculated. Results: The study cohort included 148 thyroid cancer patients and 76% were female. All cases were papillary thyroid cancer and most diagnoses were classified as T2 (42%), N0 (55%), M0 (91%), and stage 1 (83%). Nearly all patients (n = 147) had complete thyroidectomy. Levels of thyroglobulin and thyroglobulin antibodies (TgAb) were low overall, with only 5% of the study cohort deemed TgAb positive. Mean levels of thyroid stimulating hormone (TSH) measured at 2 time points (1.37 mIU/L, 1.42 mIU/L) were within normal range. About 91% of the study cohort had normal TSH levels and 82% met target TSH levels. There were 2 cases of recurrence; however, investigation determined that they were not initially appropriate candidates for transition to primary care. Nearly 99% (n = 146) of patients had excellent response to therapy, showed no evidence of disease recurrence, and have not required re-referral to specialist care. Conclusions: These findings may reassure specialists that low-risk, stable thyroid cancer patients can be safely transitioned to primary care for post-treatment follow-up.

8 June 2021 in Thyroid®
Verified
Journal Article
Closed access
NJNeha Janmohamed
Neha Janmohamed
PSPhillip Segal
Phillip Segal
ACAnn Marie Corrado
Ann Marie Corrado
Aisha LoftersAisha Lofters
Aisha Lofters
PNPatricia Nguyen
Patricia Nguyen
AZAfshan Zahedi
Afshan Zahedi
Background: Thyroid cancer patient discharge patterns from specialists are heterogeneous, with some specialists following patients for a longer period of time than others. With no well-established transitional plan, such as in breast and colorectal cancer, primary care physicians play a variable role in long-term thyroid cancer care. The objective of this study was to examine endocrinologist-perceived factors affecting the transition of care for thyroid cancer patients through a qualitative and quantitative survey of practicing endocrinologists in Ontario, Canada. Methods: All eligible practicing endocrinologists in Ontario were invited to participate in the study, via an email with an embedded survey link. Consent was assumed if the physician completed the survey. The survey collected physician demographics and asked a series of Likert-scale and open-ended questions on their views regarding transitioning care of their thyroid cancer patients. Quantitative analysis was based on mode and variability. Qualitative analysis was completed using inductive thematic analysis. Results: Seventy physicians completed the survey, with a response rate of 35.5%. Based on the responses to the Likert-scale questions, there was a lack of consensus in terms of discharging criteria for patients who had low-risk papillary thyroid cancer, stable thyrotropin levels, multiple nonthyroid-related comorbidities, and hemithyroidectomy with no disease recurrence. The majority of endocrinologists responded that the main factors affecting discharge included whether the primary care physician was able to follow their recommendations, whether the primary care physician could appropriately adjust levothyroxine doses, and whether the patient was confident that their primary care physician could manage their thyroid cancer follow-up. Themes extracted from the open-ended question also indicated that the main factors affecting the transition of care were related to the primary care physician, the patient, the imaging interpretation, and the discharge guidelines. Conclusion: The lack of consensus among endocrinologists affects the transition of patient care, and there is a need to provide clear and accurate information to primary care physicians and thyroid cancer patients on postcancer treatment care. Efforts should be sought to standardize discharge and long-term care.

16 May 2025 in European Thyroid Journal
Verified
Journal Article
Open access
PDF file
RPRalf Paschke
Ralf Paschke
SGSana Ghaznavi
Sana Ghaznavi
SISyed Ali Imran
Syed Ali Imran
JJJennifer Jacquier
Jennifer Jacquier
HLHeather Lochnan
Heather Lochnan
AZAfshan Zahedi
Afshan Zahedi
The incidence of differentiated thyroid cancer (DTC) has increased significantly in recent decades. Following initial diagnosis, DTC patients are classified according to the American Thyroid Association (ATA) as low, intermediate, and high risk for recurrence. Patients in the ATA low recurrence-risk category have a recurrence risk of ≤5%, with 20-year disease-specific mortality of <1%. Accordingly, there has been a shift to de-escalating initial treatment, including the relaxation of thyroid-stimulating hormone suppression. In addition, fewer low-risk patients undergo total thyroidectomy or radioactive iodine therapy. However, the optimal long-term surveillance strategy remains unclear, with many patients continuing follow-up in speciality clinics for many years. In addition, emerging evidence suggests that long-term surveillance can be effectively managed in primary care settings. To enhance understanding among Canadian thyroid practitioners and to improve care for Canadian patients diagnosed with low-risk DTC, we developed this consensus statement by collecting feedback from a multidisciplinary team led by one chairperson (endocrinologist), an additional eight endocrinologists, two surgeons, and one patient partner. This consensus statement reflects current evidence and expert opinion regarding initial management and long-term surveillance of low-risk DTC patients. This work is valuable to Canadian thyroid practitioners as it provides standardized guidelines to ensure optimal care and improved outcomes for low-risk DTC patients.

1 August 2024 in Thyroid®
Verified
Journal Article
Closed access
KDKaren Devon
Karen Devon
KTKathryn Tinckam
Kathryn Tinckam
AHAtul Humar
Atul Humar
AMAmin Madani
Amin Madani
JPJesse D. Pasternak
Jesse D. Pasternak
AZAfshan Zahedi
Afshan Zahedi
Background Hypoparathyroidism following thyroid surgery presents significant challenges, often leading to debilitating symptoms and reduced quality of life despite conventional treatment. We describe a patient who had a staged total thyroidectomy for low-risk thyroid cancer and developed severe refractory iatrogenic hypoparathyroidism in whom we performed the first successful fresh normal-tissue deceased donor parathyroid transplant in an immune-naïve recipient. Methods A rigorous protocol for donor selection and transplantation was developed. Donor criteria aimed at minimizing infectious and immunological risks. Surgical techniques involved retrieval and transplantation of healthy parathyroid glands from a deceased donor into the recipient's muscle tissue, followed by immunosuppression. Results Following transplantation, the patient exhibited rapid resolution of symptoms, normalization of calcium levels, and cessation of calcium supplementation. Follow-up-has revealed sustained graft function without the need for additional therapy. Conclusion Deceased donor parathyroid allotransplantation emerges as a promising therapeutic option for severe refractory hypoparathyroidism, underscoring the potential for physiologic cure and improved quality of life in patients with this debilitating complication of thyroid cancer surgery. Further research is warranted to validate the efficacy and safety of this innovative approach.